Calliditas Therapeutics AB (CALT)
| Market Cap | 738.24M |
| Revenue (ttm) | 46,243 |
| Net Income (ttm) | -57.25M |
| Shares Out | 24.97M |
| EPS (ttm) | -2.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $29.50 |
| Previous Close | $29.13 |
| Change ($) | 0.37 |
| Change (%) | 1.26% |
| Day's Open | 29.61 |
| Day's Range | 29.34 - 30.00 |
| Day's Volume | 12,374 |
| 52-Week Range | 21.00 - 38.00 |
STOCKHOLM and BAD VILBEL, Germany, July 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas") and STADA Arzneimittel AG ("STADA") announced today t...
STOCKHOLM, July 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed a loan agreement of up to the Euro...
STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company submitted a Marketing Authorisation Applicatio...
STOCKHOLM, May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2...
STOCKHOLM, May 27, 2021 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on May 27, 2021. Adoption of income s...
STOCKHOLM, May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary an...
STOCKHOLM, May 14, 2021 /PRNewswire/ -- On May 18 th, 2021, Calliditas Therapeutics AB (publ) ("Calliditas") will publish its financial report for the first quarter of 2021, and at 2.30 pm CET will host...
STOCKHOLM, May 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that former Head of North America Commercial, Andrew Udell, has ...
STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces today that the Board has decided that the interim report for the first quarter 202...
STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's website: w...
STOCKHOLM, April 26, 2021 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on ...
Calliditas Therapeutics (NASDAQ: CALT) has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy (I...
STOCKHOLM, Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant and clin...
Calliditas Therapeutics AB (NASDAQ: CALT) has dosed that first patient in the global open-label extension part of Phase 3 study (dubbed as NefIgArd) that will offer a 9-month treatment with Nefecon to a...
Undervalued stocks that are likely to surge higher in the next few quarters supported by company specific catalysts and industry tailwinds. The post 4 Undervalued Stocks That Could Rip Higher appeared f...
STOCKHOLM, Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depositary Shares ("...
STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase...
STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed in accordan...
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstratio...
STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also h...
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nef...
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced positive topline results from Part A of the global Phase 3 clinical t...
STOCKHOLM, Sept. 30, 2020 /PRNewswire/ -- During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company's warrant program issued in 2017. Thus, as of Septembe...
Successful capital raise on NASDAQ STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- "In June we successfully closed a $90m U.S.
STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020.
Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.
About CALT
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jun 5, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol CALT |
Financial Performance
In 2020, CALT's revenue was 874,000, a decrease of -99.53% compared to the previous year's 184.83 million. Losses were -433.49 million, 1,230.6% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is 51.20, which is an increase of 73.56% from the latest price.